SEVER LIFE SCIENCES B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), TO SHARE PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR OCULAR SURFACE CONTROL, DURING AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2026

ConferenceLACRIFILL® Canalicular GelPositive

AI Analysis

Summary

Nordic Pharma, a subsidiary of Sever Life Sciences B.V., will present patient data and experience study results for LACRIFILL® Canalicular Gel at the American Academy of Ophthalmology Annual Meeting in October 2026.

Importance:3/10

Sentiment:

0.30

conferencepatient dataophthalmologyAAO 2026

Related Companies

$AHR $SURF

Read the original article

Published by PR Newswire Clinical Trials on October 7, 2026 2:07 PM

Read Original